

## **REMARKS**

### **Status of the Claims**

Following entry of the present amendment, claims 1, 7, 9, and 14 will be pending. Claims 2-6, 8, 10-13, and 15 have been cancelled without prejudice to or disclaimer of the subject matter therein. In addition, claim 1 has been amended to delete non-elected subject matter. Applicants expressly reserve the right to file divisional applications directed to all of the deleted subject matter. No new matter has been added by way of amendment.

### **Response to the Restriction Requirement**

The Office Action states restriction of the instant application is required under 35 USC §121 and requires the Applicants to elect a single invention from one of the following groups:

**Group I:** The compound or composition of the general formula (I) according to Claim 1, wherein D is an optionally substituted imidazopyridine ring and A is an optionally substituted 6-membered heterocyclic ring containing one nitrogen, according to Claims 1-14;

**Group II:** The compound or composition of the general formula (I) according to Claim 1, wherein D is an optionally substituted imidazopyridine ring and A is an optionally substituted 5-membered heterocyclic ring containing at least one nitrogen, according to Claims 1-14;

**Group III:** The compound or composition of the general formula (I) according to Claim 1, wherein D is an optionally substituted imidazopyridine ring and A is an optionally substituted phenyl ring, according to Claims 1-14;

**Group IV:** The compound or composition of the general formula (I) according to Claim 1, wherein D is an optionally substituted benzimidazole ring and A is an optionally substituted 6-membered heterocyclic ring containing one nitrogen, according to Claims 1-14.

**Group V:** The compound or composition of the general formula (I) according to Claim 1, wherein D is an optionally substituted benzimidazole ring and A is an optionally substituted 5-membered heterocyclic ring containing at least one nitrogen, according to Claims 1-14;

**Group VI:** The compound or composition of the general formula (I) according to Claim 1, wherein D is an optionally substituted benzimidazole ring and A is an optionally substituted phenyl ring, according to Claims 1-14;

**Group VII:** The compound or composition of the general formula (I) according to Claim 1, wherein D is an optionally substituted imidazopyridazine ring and A is an optionally substituted 6-membered heterocyclic ring containing one nitrogen, according to Claims 1-14;

**Group VIII:** The compound or composition of the general formula (I) according to Claim 1, wherein D is an optionally substituted imidazopyridazine ring and A is an optionally substituted 5-membered heterocyclic ring containing at least one nitrogen, according to Claims 1-14;

**Group IX:** The compound or composition of the general formula (I) according to Claim 1, wherein D is an optionally substituted imidazopyridazine ring and A is an optionally substituted phenyl ring, according to Claims 1-14;

**Group X:** The compound or composition of the general formula (I) according to Claim 1, not previously mentioned in Groups I-IX, according to Claims 1-14; and

**Group XI:** A method of treating a disorder, comprising administering a compound or composition of Claim 1 according to one of the above Groups, according to Claim 15.


Applicants elect to prosecute Group III. Claims 1, 7, 9, and 14 are directed to the elected invention. Applicants expressly reserve the right to file divisional applications on the non-elected subject matter.

The Examiner has further required the election of a single species for prosecution on the merits. Applicants elect to prosecute 3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-phenylpyrazin-2-amine. Claims 1, 7, 9, and 14 read on the elected species.

Applicants respectfully request entry of the above amendment and examination of claims 1, 7, 9, and 14. Additionally, Applicants believe the present claims are in condition for allowance and such action is respectfully requested. Applicants believe that no other fees are due in connection with the filing of this paper other than those specifically authorized herewith.

Should any other fees be deemed necessary to effect the timely filing of this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392. If the Examiner has any outstanding issues with the pending claims, he is encouraged to telephone the undersigned at (919) 483-1467 for expeditious handling.

Respectfully submitted,

  
Kathryn L. Coulter  
Attorney for Applicant  
Registration No. 45,889

Date: 4/17/2008  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1467  
Facsimile: (919) 483-7988